Published in Eur Urol on March 03, 2009
Fluorescence imaging in surgery. IEEE Rev Biomed Eng (2013) 1.14
Intraoperative optical imaging and tissue interrogation during urologic surgery. Curr Opin Urol (2014) 0.95
Efficacy of 5-aminolevulinic acid-mediated photodynamic therapy using light-emitting diodes in human colon cancer cells. Oncol Rep (2013) 0.84
A ratiometric threshold for determining presence of cancer during fluorescence-guided surgery. J Surg Oncol (2015) 0.78
Nondestructive testing in urologic oncology. Eur Urol (2009) 0.75
Performance of 5-aminolevulinic-acid-based photodynamic diagnosis for radical prostatectomy. BMC Urol (2015) 0.75
Hemodynamic effects of orally administered delta-ALA during radical prostatectomy. World J Urol (2011) 0.75
Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med (2011) 12.52
Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res (2002) 5.99
Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol (2002) 5.20
Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet (2007) 5.19
Frequent EpCam protein expression in human carcinomas. Hum Pathol (2004) 4.94
Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol (2010) 4.60
Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies. Eur Urol (2009) 4.58
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst (2010) 4.54
A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol (2007) 4.37
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Prevalence of human gammaretrovirus XMRV in sporadic prostate cancer. J Clin Virol (2008) 4.25
Pelvic lymph node dissection in prostate cancer. Eur Urol (2009) 3.93
Urethral stricture: etiology, investigation and treatments. Dtsch Arztebl Int (2013) 3.57
Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol (2008) 3.50
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet (2011) 3.37
HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol (2009) 3.37
Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol (2008) 3.37
Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. J Clin Oncol (2009) 3.36
Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet (2002) 3.32
Virtual autopsy as an alternative to traditional medical autopsy in the intensive care unit: a prospective cohort study. Ann Intern Med (2012) 3.29
Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy. Eur Urol (2012) 3.26
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol (2009) 3.14
Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell (2013) 3.08
The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients. Int J Radiat Oncol Biol Phys (2010) 3.06
Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol (2009) 2.99
Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol (2009) 2.97
A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. Lancet Oncol (2011) 2.89
Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res (2005) 2.85
Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol (2005) 2.83
Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J Clin Oncol (2011) 2.78
Perioperative mortality is significantly greater in septuagenarian and octogenarian patients treated with radical cystectomy for urothelial carcinoma of the bladder. Urology (2011) 2.76
Downsides of robot-assisted laparoscopic radical prostatectomy: limitations and complications. Eur Urol (2009) 2.76
Systematic review and meta-analysis of perioperative outcomes and complications after robot-assisted radical prostatectomy. Eur Urol (2012) 2.74
Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol (2003) 2.72
Prevalence of a tertiary Gleason grade and its impact on adverse histopathologic parameters in a contemporary radical prostatectomy series. Eur Urol (2008) 2.72
Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet (2011) 2.72
Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene (2003) 2.71
Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications. Eur Urol (2009) 2.60
Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res (2004) 2.55
International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2002) 2.51
Validation of the contemporary epstein criteria for insignificant prostate cancer in European men. Eur Urol (2007) 2.50
Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol (2010) 2.48
Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol (2008) 2.48
POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. Cancer Res (2003) 2.45
A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet (2012) 2.45
Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol (2009) 2.45
Chronic kidney disease after nephrectomy in patients with small renal masses: a retrospective observational analysis. Eur Urol (2012) 2.45
Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Nat Genet (2004) 2.44
Laser therapy for upper urinary tract transitional cell carcinoma: indications and management. Eur Urol (2008) 2.43
Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. Eur Urol (2012) 2.43
Marked gene transcript level alterations occur early during radical prostatectomy. Eur Urol (2007) 2.41
Prevalence of KIT expression in human tumors. J Clin Oncol (2004) 2.40
ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer. Eur Urol (2007) 2.40
A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology (2003) 2.40
GreenLight laser vaporization of the prostate: single-center experience and long-term results after 500 procedures. Eur Urol (2008) 2.33
Expression and prognostic relevance of annexin A3 in prostate cancer. Eur Urol (2008) 2.32
Prevalent overexpression of prolyl isomerase Pin1 in human cancers. Am J Pathol (2004) 2.32
Evaluation of prostate cancer detection with ultrasound real-time elastography: a comparison with step section pathological analysis after radical prostatectomy. Eur Urol (2008) 2.31
Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res (2005) 2.31
WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol (2003) 2.30
Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol (2010) 2.30
Comorbidity and performance indices as predictors of cancer-independent mortality but not of cancer-specific mortality after radical cystectomy for urothelial carcinoma of the bladder. Eur Urol (2012) 2.28
Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study. Eur Urol (2013) 2.26
Mid-term results for the retroluminar transobturator sling suspension for stress urinary incontinence after prostatectomy. BJU Int (2010) 2.26
Topographical anatomy of periprostatic and capsular nerves: quantification and computerised planimetry. Eur Urol (2008) 2.22
Frozen section for the management of intraoperatively detected palpable tumor lesions during nerve-sparing scheduled radical prostatectomy. Eur Urol (2006) 2.21
Propensity-score-matched comparison of perioperative outcomes between open and laparoscopic nephroureterectomy: a national series. Eur Urol (2011) 2.20
Systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy. Eur Urol (2007) 2.16
Nerve quantification and computerized planimetry to evaluate periprostatic nerve distribution-does size matter? Urology (2009) 2.14
High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat (2004) 2.14
The "all-seeing needle": initial results of an optical puncture system confirming access in percutaneous nephrolithotomy. Eur Urol (2011) 2.13
A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes. Eur Urol (2011) 2.11
Repeat retrourethral transobturator sling in the management of recurrent postprostatectomy stress urinary incontinence after failed first male sling. Eur Urol (2010) 2.11
The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Res Treat (2005) 2.10
Dual energy CT characterization of urinary calculi: initial in vitro and clinical experience. Invest Radiol (2008) 2.08